Walden Daniel, Eslinger Cody, Bekaii-Saab Tanios
Mayo Clinic Arizona, Scottsdale, AZ, USA.
Division of Hematology/Medical Oncology, Mayo Clinic Cancer Center, 5881 E. Mayo Blvd., Phoenix, AZ 85054, USA.
Therap Adv Gastroenterol. 2022 Aug 6;15:17562848221115317. doi: 10.1177/17562848221115317. eCollection 2022.
Biliary tract cancers are a diverse and aggressive malignancy that carry a poor chance for curative treatment and significant associated mortality. Current first-line treatment only extends median overall survival to roughly 1 year and is associated with a significant adverse event profile. Recently, advancements in genetic sequencing have opened new avenues of targeted treatment. In cholangiocarcinoma, FGFR2 alterations have been shown to be present in roughly 10-15% of intrahepatic cholangiocarcinoma. Pemigatinib, a FGFR1-4 inhibitor, has been shown to significantly extend survival in the second-line setting to over 20 months in patients who harbor FGFR2 fusions. Here, we outline the development and future direction of pemigatinib and other FGFR2 inhibitors in the field of advanced biliary tract cancers.
胆管癌是一种多样且侵袭性强的恶性肿瘤，治愈性治疗的机会渺茫，相关死亡率很高。目前的一线治疗仅将中位总生存期延长至约1年，且伴有显著的不良事件。最近，基因测序的进展开辟了靶向治疗的新途径。在胆管癌中，约10%-15%的肝内胆管癌存在FGFR2改变。培米替尼是一种FGFR1-4抑制剂，已被证明可使携带FGFR2融合的患者在二线治疗中的生存期显著延长至20多个月。在此，我们概述了培米替尼和其他FGFR2抑制剂在晚期胆管癌领域的发展及未来方向。
